Drugs / AD-SVF
AD-SVF
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07230600 | Nov 2025 → Dec 2026 expected | adhesions of uterus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05857358 | Jan 2024 → Feb 2026 overdue | — | Assistance Publique Hopitaux De Marseille | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT02912169 | Nov 2015 → Nov 2017 | Alzheimer disease | Ageless Regenerative Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02087397 | Mar 2014 → Nov 2017 | erectile dysfunction | Ageless Regenerative Institute | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01739504 | Mar 2014 → Apr 2017 | osteoarthritis | Ageless Regenerative Institute | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-SVF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07230600 ↗ |
| Known as | Adipose-Derived Stromal Vascular Fraction | “This will be an open-label, non-randomized, multi-center, patient sponsored study of Adipose-Derived Stromal Vascular Fraction (AD-SVF) implantation performed intra-articularly...” NCT01739504 ↗2“The cell therapy unit processes and controls the experimental product (adipose-derived stromal vascular fraction; AD-SVF) from the harvested adipose tissue.” NCT05857358 ↗ “adipose-derived stromal vascular fraction (AD-SVF) therapy” NCT07230600 ↗ |
| Known as | Autologous Adipose-derived Stromal Vascular Fraction | “Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF) will be infused intra-venous and Intra nasal.” NCT02912169 ↗ |
| Modality | Cell therapy | “Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.” NCT01739504 ↗ |
| Route | Other | “intra-articular administration of affected joint.” NCT01739504 ↗ |